Financials

People

Activity

Third Rock Ventures

Company

Investment-firm

Financing round

General

About Company
Third Rock Ventures invests in high-growth potential life science companies that can make a difference in the marketplace.

Industry

Sector :

Subsector :

Keywords :

founded date

01.01.2007

Number of employees

IPO status

Private

Description

Founded in Boston in 2007, Third Rock Ventures is a healthcare venture capital firm that invests in companies operating in the healthcare, medicine, life sciences, drugs, devices and diagnostics, therapeutics, and information technology sectors. The firm focuses on advancing disruptive areas of science and medicine to deliver breakthroughs to patients. Third Rock Ventures aims to discover, launch and build innovative companies that can transform the lives of patients. The company works with leading scientific and business visionaries as well as industry partners to identify opportunities to change the future of medicine. The firm is actively involved in the early stages of its companies’ development, typically serving as members of the founding management teams, to build a strong foundation, put in place the right people and culture, and set the companies on a path to scientific and operational excellence. Third Rock Ventures believes in the companies it launches and makes big initial investments, often complemented by strategic alliances, to enable its companies to advance life-changing therapies, devices and diagnostics.
Contacts

Contact Email

Phone number

Social url

Similar Companies
1000
Malin Corporation

Malin Corporation

Malin Corporation is a venture capital firm based in Dublin that invests in innovative life sciences and healthcare technologies.

Sector

General Industrials

Subsector

Diversified Industrials

Keywords

Biotechnology, Medical Device, Financial Services

Location

Dublin, Ireland

total rounds

1

total raised

$55.92M

count Of Investments

15

count Of Exists

3
Birk Venture

Birk Venture

Birk Venture is a Scandinavian venture capital firm that focuses on investing in early-stage companies in the life science industry.

Sector

General Industrials

Subsector

Diversified Industrials

Location

Oslo, Norway

count Of Investments

9
Rhapsody Venture Partners

Rhapsody Venture Partners

Rhapsody Venture Partners invests in and operates industrial science start-ups.

Sector

General Industrials

Subsector

Diversified Industrials

Location

Cambridge, MA, USA

count Of Investments

37
Axcend Health

Axcend Health

Axcend Health is a global venture-building firm that invests in innovative teams and companies around cutting edge advances in life science.

Sector

General Industrials

Subsector

Diversified Industrials

Location

Warsaw, Poland

Financials

Investments
109
Date 
name 
Lead 
type 
Raised 
Marea Therapeutics

Marea Therapeutics

Marea is a biotechnology firm that uses the advancements in human genetics next-generation medications for cardiometabolic illnesses.

total rounds

2

total raised

$190M
Marea Therapeutics

Marea Therapeutics

Marea is a biotechnology firm that uses the advancements in human genetics next-generation medications for cardiometabolic illnesses.

total rounds

2

total raised

$190M
Syncopation Life Sciences

Syncopation Life Sciences

Syncopation Life Sciences is advancing a new generation of adoptive cell therapies for cancers.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Therapeutics

Location

Palo Alto, CA, USA

total rounds

3

total raised

$310M
Co-Investors
Exits
11
Afferent Pharmaceuticals

Afferent Pharmaceuticals

Afferent Pharmaceuticals is developing medicines to treat chronic pain.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

San Mateo, CA, USA

total rounds

4

total raised

$83.15M
Corvia Medical

Corvia Medical

Corvia Medical is revolutionizing heart failure treatment with a novel transcatheter structural heart device.

Sector

Medical Equipment and Services

Subsector

Medical Equipment

Keywords

Medical Device, Health Care, Medical

Location

Andover, MA, USA

total rounds

6

total raised

$119.41M
Foundation Medicine

Foundation Medicine

Foundation Medicine creates personalized cancer therapies using genetic sequencing technology.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Health Care, Biotechnology, Medical

Location

Cambridge, MA, USA

total rounds

4

total raised

$96.5M

count Of Investments

2

People

Founders
3
Robert Tepper
Robert Tepper

Robert Tepper

Bob Tepper is a co-founder of Third Rock Ventures and a distinguished scientist with more than 30 years of experience building and operating leading R&D organizations in the biotech industry. Bob focuses on the formation, development and scientific strategy of our portfolio companies, as well as actively identifying and evaluating new investments. Prior to joining Third Rock, Bob was president of R&D at Millennium Pharmaceuticals and was vital in its expansion from a drug discovery company to a fully integrated biopharmaceutical company. Earlier, Bob co-founded Cell Genesys/Abgenix. Bob holds an A.B. in biochemistry from Princeton University and received his M.D. from Harvard Medical School. Bob currently serves as an adjunct faculty member at Harvard Medical School and Massachusetts General Hospital and is an advisory board member of several leading health care institutions, including the Partners HealthCare Center for Personalized Genetic Medicine, Harvard Medical School and Tufts Medical School. Bob is on the Board of Overseers at Tufts University. He also serves on the Council of the National Center for the Advancement of Translational Sciences (NCATS) at the National Institutes of Health (NIH). Bob participated in the 1972 Olympic Games in Munich, Germany.

current job

Third Rock Ventures
Third Rock Ventures

Robert Tepper

Mark Levin
Mark Levin

Mark Levin

Mark Levin is the Interim CEO, a member of the Board of Directors, and a Partner at Third Rock Ventures. He is an industry visionary with 40 years of experience, including more than 30 years of launching and building leading biotech companies. Mr. Levin co-founded Third Rock Ventures in 2007 and focuses on the formation, development, and business strategy of its portfolio companies, as well as actively identifying and evaluating new investments. Before Third Rock, Mr. Levin was co-founder of Mayfield Fund's life sciences effort, where he was also the founding CEO of Tularik, Cell Genesys/Abgenix, Focal, Stem Cells, and Millennium Pharmaceuticals. Mr. Levin served as CEO of Millennium Pharmaceuticals for 12 years. Earlier in his career, he was an engineer and project leader at Eli Lilly and Genentech. He is a member of the National Academy of Engineering and the Friends of Personalized Medicine, and he co-founded the Possible Project in Cambridge, Mass. Mr. Levin holds an M.S. in chemical and biochemical engineering from Washington University.

current job

Third Rock Ventures
Third Rock Ventures

Mark Levin

Kevin Starr
Kevin Starr

Kevin Starr

Kevin Starr is a proven operational leader with more than 25 years of experience building and operating leading biotech companies. Mr. Starr co-founded Third Rock Ventures in 2007 and focuses on the formation, development, and business strategy of the firm's portfolio companies as well as actively identifying and evaluating new investments. Before Third Rock Ventures, Mr. Starr was Chief Operating Officer and Chief Financial Officer at Millennium Pharmaceuticals, where he led key roles in raising billions of dollars in capital through strategic alliances and public financing and driving growth through company expansion and mergers and acquisitions. Earlier in his career, he served in various executive roles at Millennium BioTherapeutics, Biogen, and Digital Equipment Corporation. He is currently a Board Member and Start-Up CEO of Sage Therapeutics. Mr. Starr holds an M.S. in Corporate Finance from Boston College and a B.A. in Mathematics and Business from Colby College.

current job

Ember Therapeutics
Ember Therapeutics

Kevin Starr

Employee Profiles
120
Kevin Munnelly

Kevin Munnelly

Senior Vice President Of Technology

Kyle Elrod

Full time consultant

Lorence Kim

Lorence Kim

Venture Partner

David Kaufman

David Kaufman

Venture Partner

Zoe Angell

Zoe Angell

Senior Executive Assistant

Richard Ransohoff

Richard Ransohoff

Venture Partner

Kelly Moynihan

Senior associate

Jeffrey Tong

Jeffrey Tong

Partner

Activity

Recent News
15
News Timeline

The graph reveals the ratio (%) of positive news articles in a chosen time range

month